InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,762.48
(
0.42%
)
US TECH 100
19,522.80
(
0.00%
)
Dow Jones
42,330.15
(
0.04%
)
Brent Oil
71.12
(
-1.21%
)
Bitcoin
63,997.00
(
1.05%
)
Post# of 253261
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jbog

Send PM Follow Ignore
Followers 61
Posts 11584
Boards Moderated 0
Alias Born 07/16/2006

jbog

Re: ghmm post# 215055

Monday, 11/13/2017 7:10:10 AM

Monday, November 13, 2017 7:10:10 AM

Post# of 253261
ghmm bmy-nktr


Nektar price target raised to $44 from $27 at JPMorgan JPMorgan analyst Jessica Fye raised her price target for Nektar Therapeutics to $44 saying she views the company's STIC data as a "win" given the "encouraging response rates" in both PD-L1 positive and negative patients. The analyst sees increased potential for Nektar to access the large lung market and raised her probability of success to 45% and peak sales for NKTR-214 to $4B. Fye keeps an Overweight rating on Nektar.

Read more at:
https://thefly.com/landingPageNews.php?id=2640622
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up